Comparing the current results to its competitors, Tevogen Bio Holdings Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.9 %, recorded in the same quarter.
Tevogen Bio Holdings Inc 's Comment on Competition and Industry Peers
The company recognizes competition from established and emerging pharmaceutical and biotechnology firms, governmental agencies, academic institutions, and public and private research organizations. Competitors may possess greater financial resources and expertise in areas such as research and development, clinical trials, manufacturing, regulatory approvals, and marketing. Smaller or early-stage companies may also pose competition, particularly through collaborations with larger entities. Competition extends to recruiting qualified personnel, establishing clinical trial sites, enrolling patients, and acquiring complementary technologies.
The company is developing TVGN 489 to address gaps in COVID-19 therapeutics for immunocompromised individuals, high-risk elderly patients, and those with Long COVID. Currently, only one FDA-licensed product exists for COVID-19 treatment specific to the immunocompromised population, which provides passive immunity through high-titer COVID-19 convalescent plasma (CCP) supplied by OneBlood, a non-profit blood donation center. The company believes TVGN 489 may offer advantages over Veklury, which requires multiple infusions, and Paxlovid, which involves daily dosing, potential drug interactions, and reports of disease relapse or rebound.
July 18, 2025
WARREN, N.J., July 18, 2025 Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a biotech company specializing in innovative immunotherapy solutions, has made significant strides in artificial intelligence as it merges cutting-edge technology with healthcare. Recently, the International Bureau of the World Intellectual Property Organization (WIPO) published Tevogen s international patent application d “Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models” (Publication No. WO 2025/129197). This milestone marks a critical advancement in the company’s mission to utilize AI in predicting effective immunological responses, paving the way for improved therapies. A New Head...
July 10, 2025
In the burgeoning landscape of biopharmaceutical innovation, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is making decisive strides toward becoming a transformative force within the industry. The company recently celebrated a significant milestone with the inauguration of its new corporate headquarters in Warren, New Jersey, fully funded by the remarkable generosity of its Founder and CEO, Dr. Ryan Saadi. This strategic move not only exemplifies Saadi’s profound commitment to the company s mission but also underscores Tevogen’s innovative business model aimed at revolutionizing healthcare through cost-efficient, value-driven strategies.The new headquarters in Warren is designed to centralize the company’s...
November 5, 2024
Leveraging Artificial Intelligence to Enhance HPV Target Identification: Tevogen Bio and Microsoft Partnership Tevogen Bio Holdings Inc. a clinical-stage biotechnology firm, has recently announced a strategic partnership with Microsoft to enhance its efforts in target identification for the treatment of Human Papillomavirus (HPV). This collaboration aims to utilize advanced machine learning techniques through Tevogen s Artificial Intelligence initiative, Tevogen.AI, underscoring the importance of technological integration in the advancement of next-generation immunotherapies. Human Papillomavirus (HPV) is a significant global health concern, with several strains linked to various cancers, particularly cervi...
October 15, 2024
: Tevogen Bio, a clinical-stage specialty immunotherapy company, has made significant strides in the development of off-the-shelf, genetically unmodified T-cell therapies. Recent publications highlighting promising Phase I clinical trial data for TVGN 489, a SARS-CoV-2 specific immunotherapy, offer a glimpse into the potential of these therapeutics in treating both infectious diseases and cancers. Additionally, the company’s proactive engagement with U.S. Congress underscores its commitment to advocating for long COVID patients. This article explores the implications of Tevogen s recent achievements for the company’s future and its role in shaping biotechnology innovation. In the ever-evolving arena o...
July 10, 2024
Tevogen Bios RandD Leadership Discusses the Revolutionary Potential of Genetically Unmodified T Cell Technology for Treating Infectious Diseases, Cancers, and Neurological DisordersWARREN, N.J., July 10, 2024 - In a recent interview with Nasdaq s Kristina Ayanian, Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. (Nasdaq: TVGN) shed light on the groundbreaking potential of their genetically unmodified, off-the-shelf T cell therapy in the fields of oncology, neurology, and virology. As pioneers in the field of specialty immunotherapy biotechnology, Tevogen is dedicated to making T cell therapy mainstream and revolutionizing the way we approach the treatment of a wide range of diseases.T cell...
June 25, 2024
Tevogen Bio Announces Positive Phase I Results for TVGN 489 in Blood Advances: A Promising Leap in COVID-19 Immunotherapy Warren, N.J., June 25, 2024 Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a trailblazer in the clinical-stage specialty immunotherapy domain, has announced the publication of its phase I clinical trial data for TVGN 489. This investigational therapy, consisting of allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocytes (CTLs), has been officially reported in the prestigious journal Blood Advances . Tevogen Bio’s groundbreaking work focuses on developing off-the-shelf, genetically unmodified T cell therapies targeting oncology, neurology, and virology. Groundbreaking ResultsThe phase...
May 10, 2024
In a significant development for the biotechnology sector, Tevogen Bio, a pioneering research and development firm, has successfully secured up to $50 million in financing. This substantial boost will not only propel the company s operational s but also establish a robust financial pathway towards positive cashflow, all while ensuring minimal dilution. In this article, we explore the implications of this funding announcement in detail, examining how it stimulates Tevogen Bio s growth prospects and accelerates their mission to revolutionize healthcare.Enhancing Operational s:The infusion of $50 million in financing provides Tevogen Bio with a remarkable opportunity to ramp up its operational s. By expanding t...
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Sources:
Tevogen Bio Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tevogen Bio Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
